Page 4 - Repligen Corp News Today

Pitcairn Co. lowered its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,263 shares of the biotechnology company’s stock after selling 290 shares during the period. Pitcairn Co.’s holdings in Repligen […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among […]

StockNews.com assumed coverage on shares of Repligen (NASDAQ:RGEN – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. RGEN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft cut their price objective on Repligen from $180.00 to $165.00 in a […]

First Trust Advisors LP grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 197.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,191 shares of the biotechnology company’s stock after buying an additional 89,724 shares during the period. First Trust […]

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 170,205 shares of the biotechnology company’s stock after purchasing an additional 11,028 shares during the […]

Raymond James & Associates lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,911 shares of the biotechnology company’s stock after selling 529 shares during the quarter. Raymond […]

California Public Employees Retirement System trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,450 shares of the biotechnology company’s stock after selling 8,870 shares during the period. California Public Employees […]

Skandinaviska Enskilda Banken AB publ bought a new position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 9,679 shares of the biotechnology company’s stock, valued at approximately $1,639,000. Several other hedge funds have also modified […]

Repligen Co. (NASDAQ:RGEN – Get Rating) Director Martin D. Madaus acquired 500 shares of the business’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $156.18 per share, with a total value of $78,090.00. Following the purchase, the director now directly owns 1,611 shares in the company, […]

Operator: Good day, ladies and gentlemen, and welcome to the Repligen First Quarter of 2023 Earnings Conference Call. My name is Vaishnavi, and I will be your coordinator.